US20050095232A1 - Vaginal care composition - Google Patents

Vaginal care composition Download PDF

Info

Publication number
US20050095232A1
US20050095232A1 US10/977,742 US97774204A US2005095232A1 US 20050095232 A1 US20050095232 A1 US 20050095232A1 US 97774204 A US97774204 A US 97774204A US 2005095232 A1 US2005095232 A1 US 2005095232A1
Authority
US
United States
Prior art keywords
vaginal
care composition
zinc
vaginal care
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/977,742
Inventor
Peter-Hansen Volkmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20050095232A1 publication Critical patent/US20050095232A1/en
Priority to US11/599,965 priority Critical patent/US7670606B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms

Definitions

  • the present invention relates to a vaginal care composition.
  • the invention relates to a vaginal care composition which is introduced directly into the vagina in the form of an ovule, a cream or an ointment or with a tampon or which is brought into a position outside the vagina on a panty liner.
  • mucosae can be very sensitive.
  • the mucosa of the vagina is particularly sensitive to irritations or inflammations. Women who are so predisposed react, for example after visiting a swimming pool or other body of water or after sexual intercourse, with irritations, painful changes or even inflammation in the region of the vaginal mucosa. Hormonal changes, for example when taking the pill (“contraceptive pill”), in pregnancy, lactation or during the menopause, can also cause an irritated reaction in the vaginal mucosa. Similarly, systemic treatment with antibiotics, for example, also causes irritations of the mucosae, in particular the vaginal mucosa.
  • a further irritating factor for the vaginal flora is the increasing discharge from the vagina, which originally comes from the abdominal cavity and, owing to an unphysiological composition of the secretions, can disturb the normal balance of the vaginal population.
  • the resulting irritations of the vaginal mucosa are not only painful but can also develop into advancing inflammations, which can affect other organs or the woman's entire body. In fact, several hundred thousand women are affected each year by such irritations, which can impair their feeling of well-being considerably.
  • biofilms may be involved in the formation of/colonization with pathogenic microorganisms and/or affect them in a supporting manner or even inhibit them. It would therefore be desirable to prevent such pathological biofilms from developing.
  • the formation of a physiological mucosa-protecting film is the aim of this application.
  • the mucosa should be cared for in such a manner that it is better able to withstand environmental influences and does not offer an environment in which pathological biofilms are able to develop.
  • care has already been widely practiced for a long time, for example for the outer skin of the body, for example by the use of caring oils or creams, preferably on a regular basis, but in particular after the skin has been exposed to particular stresses, for example after sunbathing or after showering or swimming.
  • tampons For protection against infections when visiting swimming pools, there are tampons which are intended to prevent such infections.
  • These “Symbiofem” tampons which are to be found, for example, on the website www.symbiofem.com, are impregnated with Vaseline oil.
  • these tampons provide only a purely mechanical barrier layer which does not contribute to caring for the vaginal mucosa in any way.
  • contact with highly concentrated Vaseline oil is beneficial to the mucosal environment.
  • the Vaseline oil prevents a tampon from expanding in the required manner, so that it is barely able to adapt exactly to the body shape of the wearer and, in the end, water will nevertheless be allowed through.
  • the object of the present invention is to provide a vaginal care composition with which the mucosa of the vagina can be protected.
  • the invention comprises a vaginal care composition
  • a vaginal care composition comprising viable Lactobacillus and/or Bifidobacterium microorganisms, preferably Lactobacillus bifidus ; non-viable Saccharomyces cultures, preferably Saccharomyces cerevisiae ; saccharide(s); vitamin A/retinol, and zinc.
  • Lactobacillus is the microorganism that is preferably used. It is preferably selected from the group consisting of: Lactobacillus bifidus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus jensenii, Lactobacillus gasseri, Lactobacillus cellobiosis, Lactobacillus brevis, Lactobacillus delbrueckii, Lactobacillus rogosae and Lactobacillus bifidum.
  • Bifidobacterium alone or in admixture with the above Lactobacillus . It is preferably selected from: Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium adolescentis or Bifidobacterium longum.
  • the above species can be used alone or in the form of a mixture of two or more species.
  • the microorganisms are present in the composition in lyophilised or heat-dried form. In any case, they must be present in the composition in a viable manner which allows them to grow and multiply on contact with moisture (which originates, for example, from the vaginal environment).
  • Saccharomyces cerevisiae The preferred Saccharomyces species is Saccharomyces cerevisiae . This is present in the composition in the form of a culture, e.g. in dried form.
  • the Saccharomyces culture must not be viable, so that it does not compete with Lactobacillus or Bifidobacterium ; it serves as the starting material for the growth of the Lactobacilli /Bifidobacteria and as the nutrient medium for their further multiplication.
  • composition additionally comprises selenium, especially selenium-containing yeast, preferably in an amount of from 0.001 to 0.06 wt. % selenium.
  • Selenium is an antioxidant trace element with cell-protecting properties, which particularly promotes the growth of Lactobacilli and Bifidobacteria and therefore furthers their development over other microorganisms in the vagina.
  • Another embodiment additionally comprises Melaleuca aetheroleum , preferably in an amount of from 0.5 to 10 wt. %, and/or camomile flower extract, preferably in an amount of from 0.01 to 5 wt. %. Both substances assist in the care of the vaginal mucosa by their inflammation-relieving and caring properties.
  • the vaginal care composition additionally comprises D-alpha-tocopherol, preferably in an amount of from 0.5 to 5 wt. %, and/or pantothenate, preferably in an amount of from 0.1 to 3 wt. %.
  • tocopherol acts as an antioxidant for oils introduced by the composition and also as cell protection for skin and mucosa.
  • Pantothenate is a vitamin which again promotes the growth of Lactobacilli and/or Bifidobacterium over other microorganisms and (so) contributes particularly to the care of the vaginal mucosa owing to its properties as a vitamin.
  • the vaginal care composition additionally comprises fragrances, preferably natural fragrances, particularly preferably lavender oil in an amount of from 0.5 to 10 wt. %.
  • the fragrances may be present, for example, in order to make the care composition more acceptable to a potential user.
  • the vaginal care composition may comprise cocoa butter or a hard-fat carrier, for example, as the base.
  • Such carriers are known to the person skilled in the art. They are distinguished in particular by their good tolerability in the region of the vagina and do not give rise to irritations or possible allergic reactions there.
  • vaginal care composition is described by way of example hereinbelow, which composition comprises constituents in the following amounts (in the following, wt. % are always based on the total composition):
  • the saccharide for the vaginal care composition is preferably selected from: oligofructose, inulin and/or lactose, preference being given to oligofructose. It is also possible to use a mixture of two or more of the above-mentioned saccharides.
  • the saccharides serve especially as starting materials for the development of the Lactobacilli and Bifidobacteria. These utilize the saccharides and as a result have a growth advantage over other microorganisms.
  • the vaginal care composition may be so composed that the zinc is used in the form of zinc sulfate and/or zinc gluconate.
  • the vaginal care composition may also have a formulation in which the vitamin A is used in the form of retinyl acetate and/or retinyl gluconate.
  • These forms of addition of zinc and vitamin A are known to the person skilled in the art.
  • Other forms of zinc and vitamin A can be chosen, provided that the function of the composition as a care composition for the vaginal mucosa is not impaired thereby.
  • the composition may also comprise further conventional constituents, provided that they do not impair the function of a care composition.
  • constituents may be selected, for example, from binders, excipients, solvents, stabilizers, lubricants, disintegrators and carriers, such as, for example, solid or liquid carriers.
  • the vaginal care composition as defined above is used for the care of the vaginal mucosa and/or for preventing infections thereof by bacteria, fungi and/or viruses.
  • the particular composition allows the vaginal mucosa to be cared for without being adversely affected or impaired. This care can take place on a regular basis or as required, for example in phases of hormonal change, such as, for example, during pregnancy, during lactation, in the menopause or post-menopausal. It is also possible to care for the mucosa in a very targeted manner, for example before and/or after visiting public bodies of water, such as, for example, bathing pools or swimming baths.
  • the vaginal care composition is preferably applied directly to the vaginal mucosa. This can be effected, for example, by introducing the composition into the vagina in the form of an ovule or a cream or ointment and thereby bringing it into direct contact with the mucosa. It is also possible for the composition to be contained in a tampon which is then inserted into the vagina, the composition thereby coming into contact with the mucosa. Finally, according to a further preferred embodiment, the composition is contained in a panty liner. The composition is in each case activated by moisture, for example the moisture of the usual vaginal environment. “Activation” in this context means that the Lactobacilli and/or Bifidobacteria contained therein begin to grow and multiply.
  • the present invention relates to a caring ovule comprising the vaginal care composition as defined above.
  • the caring ovule having a weight of from 2 to 5 g, preferably 3 g, per ovule, preferably comprises the following per gram:
  • composition of an ovule is summarized hereinbelow in table form, the combinatory action being indicated in each case: TABLE 1 Formulation for 3 g vaginal ovules with Adeps solidus Microorganisms/g/ Formulation Content of pure Substance wt. % wt. % substance Action in the combination Lactobacillus bif . microorganisms/g 10 8 /g 10 300 mg Repopulation or control of the vaginal flora Saccharomyces cer . wt. % 2.5 75 mg Nutrient medium for symbionts and vitamin B pool Retinol acetate wt. % 0.1 Vit.
  • the term “ovule” is to include the solid forms, such as, for example, vaginal suppositories, for insertion into the vagina that are known by this name to the person skilled in the art, as well as foaming tablets or depot implants.
  • An ovule preferably comprises the conventional bases, such as, for example, Whitepsol, Massa Estarinum, coconut fat, glycerol-gelatin compositions, glycerol soaps or polyethylene glycol.
  • the present invention relates to a care cream comprising the vaginal composition as defined above.
  • the care cream preferably comprises
  • the care cream comprises further conventional cream or ointment constituents, especially constituents selected from the following group: sunflower oil, Tegomuls 90 S, cetyl alcohol, Cetaceum artificiale, Polysorbat 80, methyl 4-hydroxybenzoate, propyl 4-hydroxybenzoate, sesame oil, wool wax, yellow wax, wool wax alcohols, glycerol, glycerol esters, palmitic acid ester, white Vaseline, liquid wax, olive oil and/or distilled water.
  • cream within the scope of the present invention includes creams, ointments, as well as emulsions, and liquid compositions to be released from gelatin.
  • a particularly preferred ointment base is the following:
  • sunflower oil Tegomuls 90 S, cetyl alcohol, Cetaceum artificiale, Polysorbat 80, methyl 4-hydroxybenzoate and propyl 5-hydroxybenzoate in distilled water, or sesame oil, wool wax, yellow wax, wool wax alcohols, or glycerol, glycerol ester, palmitic acid ester, white Vaseline, liquid wax, or yellow wax, olive oil.
  • the invention relates to a caring vaginal tampon comprising the vaginal care composition as defined above.
  • the caring vaginal tampon may comprise the following (comprising from 2 to 5 g, preferably 3 g, of the vaginal care composition per tampon) (per gram of composition):
  • the caring vaginal tampon should contain the vaginal care composition on a superficial layer of the tampon, the composition being applied by spraying or immersion processes, for example.
  • the composition may also penetrate the entire tampon.
  • the vaginal care composition can also be contained solely in a layer directly beneath the outer cover layer of the tampon.
  • the vaginal care composition of the present invention can be applied to any tampon known to the person skilled in the art or such a tampon can be impregnated with the composition.
  • the tampon consists of a form twisted in on itself, with grooves or indentations directed outwardly, i.e. towards the body of the wearer, which facilitate the passage of liquid into the inside of the tampon.
  • the tampon preferably further has an outer, liquid-repelling layer and an inner liquid-storing layer. It advantageously also contains materials that swell in liquid, so that the tampon is able to adapt to the body shape of the particular wearer.
  • the tampon may have a cover layer comprising cellulose which swells on contact with liquid and without delay forms a gel, which facilitates insertion.
  • a tampon is known to the person skilled in the art.
  • the vaginal care composition according to the present invention is contained in an outer layer of the tampon, without the invention being limited thereto.
  • the invention relates to a caring panty liner comprising the vaginal care composition as defined above.
  • the caring panty liner which comprises from 2 to 4 g, preferably 3 g, of the vaginal care composition per panty liner, comprises in 1 g of the composition:
  • the caring panty liner can contain the vaginal care composition on an upper layer, preferably applied by a spraying process. It is also possible to form the caring panty liner in such a manner that the vaginal care composition is contained solely in a layer directly beneath the cover layer of the panty liner.
  • the vaginal care composition can be applied to/introduced onto any panty liner known to the person skilled in the art.
  • the panty liner may consist of a moisture-permeable cover layer, a moisture-repelling layer arranged beneath it, a moisture-storing layer arranged beneath the moisture-repelling layer, and a backing layer that is impermeable to liquid.
  • the cover layer may have pores, for example, which facilitate the drawing off of liquid and improve aeration. Masking substances which improve the appearance of the panty liner may also be present.
  • the vaginal care composition of the present invention is particularly preferably contained in a layer beneath the cover layer, without the invention being limited thereto.
  • the present care composition of the invention can also be used as a urethra stick for caring for the urethral mucosa in the case of partner care for men.
  • the care composition in this embodiment may be embedded, for example, in a urethra stick of Adeps solidus.
  • This stick should have a length of from 10 to 30 cm, preferably 25 cm, and a diameter of from 2.5 to 7 mm, preferably 4.5 mm. It can be broken into segments by means of predetermined breaking points, which are arranged, for example, at intervals of about 5 cm.
  • a preferred composition for the urethra stick consists of Lactobacillus bifidus microorganisms, with Saccharomyces cerevisiae and oligofructose as starter. Vitamin A, alpha-tocopherol, pantothenate, zinc, selenium, Melaleuca aetheroleum and fragrances should also be present.
  • the urethra stick comprises, per gram:
  • the dosage of the vaginal care composition according to the invention is dependent on factors known to the person skilled in the art; care of the mucosa is usually to be carried out from 1 to 3 times daily using up to 3 g of the composition; alternatively, immediately before and after particular stress, such as swimming or sexual intercourse. Long-term care can be carried out using, for example, 6 ovules per cycle.
  • Each ovule weighed 3 g and was prepared from the following mixture according to the processes known to the person skilled in the art for the preparation of ovules:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A vaginal care composition which is introduced directly into the vagina in the form of an ovule, a cream or an ointment or with a tampon or which is brought into a position outside the vagina on a panty liner. The composition comprises viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s); vitamin A/retinol, and zinc.

Description

    BACKGROUND OF THE INVENTION
  • The present invention relates to a vaginal care composition. In particular, the invention relates to a vaginal care composition which is introduced directly into the vagina in the form of an ovule, a cream or an ointment or with a tampon or which is brought into a position outside the vagina on a panty liner.
  • It has long been known that mucosae can be very sensitive. The mucosa of the vagina is particularly sensitive to irritations or inflammations. Women who are so predisposed react, for example after visiting a swimming pool or other body of water or after sexual intercourse, with irritations, painful changes or even inflammation in the region of the vaginal mucosa. Hormonal changes, for example when taking the pill (“contraceptive pill”), in pregnancy, lactation or during the menopause, can also cause an irritated reaction in the vaginal mucosa. Similarly, systemic treatment with antibiotics, for example, also causes irritations of the mucosae, in particular the vaginal mucosa. A further irritating factor for the vaginal flora is the increasing discharge from the vagina, which originally comes from the abdominal cavity and, owing to an unphysiological composition of the secretions, can disturb the normal balance of the vaginal population.
  • The resulting irritations of the vaginal mucosa are not only painful but can also develop into advancing inflammations, which can affect other organs or the woman's entire body. In fact, several hundred thousand women are affected each year by such irritations, which can impair their feeling of well-being considerably.
  • One theory which might explain why irritations and inflammatory reactions can develop involves the formation of biofilms. Such biofilms may be involved in the formation of/colonization with pathogenic microorganisms and/or affect them in a supporting manner or even inhibit them. It would therefore be desirable to prevent such pathological biofilms from developing. The formation of a physiological mucosa-protecting film is the aim of this application.
  • Accordingly, the mucosa should be cared for in such a manner that it is better able to withstand environmental influences and does not offer an environment in which pathological biofilms are able to develop. Such care has already been widely practiced for a long time, for example for the outer skin of the body, for example by the use of caring oils or creams, preferably on a regular basis, but in particular after the skin has been exposed to particular stresses, for example after sunbathing or after showering or swimming.
  • For protection against infections when visiting swimming pools, there are tampons which are intended to prevent such infections. These “Symbiofem” tampons, which are to be found, for example, on the website www.symbiofem.com, are impregnated with Vaseline oil. However, these tampons provide only a purely mechanical barrier layer which does not contribute to caring for the vaginal mucosa in any way. On the contrary, it is questionable whether contact with highly concentrated Vaseline oil is beneficial to the mucosal environment. Furthermore, the Vaseline oil prevents a tampon from expanding in the required manner, so that it is barely able to adapt exactly to the body shape of the wearer and, in the end, water will nevertheless be allowed through.
  • Care products for the vaginal mucosa, with which the mucosa can be similarly cared for and protected, are therefore desirable.
    • SUMMARY OF THE INVENTION
  • Accordingly, the object of the present invention is to provide a vaginal care composition with which the mucosa of the vagina can be protected.
  • The invention comprises a vaginal care composition comprising viable Lactobacillus and/or Bifidobacterium microorganisms, preferably Lactobacillus bifidus; non-viable Saccharomyces cultures, preferably Saccharomyces cerevisiae; saccharide(s); vitamin A/retinol, and zinc.
  • Lactobacillus is the microorganism that is preferably used. It is preferably selected from the group consisting of: Lactobacillus bifidus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus jensenii, Lactobacillus gasseri, Lactobacillus cellobiosis, Lactobacillus brevis, Lactobacillus delbrueckii, Lactobacillus rogosae and Lactobacillus bifidum.
  • It is also possible to use Bifidobacterium alone or in admixture with the above Lactobacillus. It is preferably selected from: Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium adolescentis or Bifidobacterium longum.
  • The above species can be used alone or in the form of a mixture of two or more species. Preferably, the microorganisms are present in the composition in lyophilised or heat-dried form. In any case, they must be present in the composition in a viable manner which allows them to grow and multiply on contact with moisture (which originates, for example, from the vaginal environment).
  • The preferred Saccharomyces species is Saccharomyces cerevisiae. This is present in the composition in the form of a culture, e.g. in dried form. The Saccharomyces culture must not be viable, so that it does not compete with Lactobacillus or Bifidobacterium; it serves as the starting material for the growth of the Lactobacilli/Bifidobacteria and as the nutrient medium for their further multiplication.
  • One embodiment of composition additionally comprises selenium, especially selenium-containing yeast, preferably in an amount of from 0.001 to 0.06 wt. % selenium. Selenium is an antioxidant trace element with cell-protecting properties, which particularly promotes the growth of Lactobacilli and Bifidobacteria and therefore furthers their development over other microorganisms in the vagina.
  • Another embodiment additionally comprises Melaleuca aetheroleum, preferably in an amount of from 0.5 to 10 wt. %, and/or camomile flower extract, preferably in an amount of from 0.01 to 5 wt. %. Both substances assist in the care of the vaginal mucosa by their inflammation-relieving and caring properties.
  • In a particularly preferred embodiment, the vaginal care composition additionally comprises D-alpha-tocopherol, preferably in an amount of from 0.5 to 5 wt. %, and/or pantothenate, preferably in an amount of from 0.1 to 3 wt. %. According to a preferred embodiment, tocopherol acts as an antioxidant for oils introduced by the composition and also as cell protection for skin and mucosa. Pantothenate is a vitamin which again promotes the growth of Lactobacilli and/or Bifidobacterium over other microorganisms and (so) contributes particularly to the care of the vaginal mucosa owing to its properties as a vitamin.
  • According to a further preferred embodiment, the vaginal care composition additionally comprises fragrances, preferably natural fragrances, particularly preferably lavender oil in an amount of from 0.5 to 10 wt. %. The fragrances may be present, for example, in order to make the care composition more acceptable to a potential user.
  • The vaginal care composition may comprise cocoa butter or a hard-fat carrier, for example, as the base. Such carriers are known to the person skilled in the art. They are distinguished in particular by their good tolerability in the region of the vagina and do not give rise to irritations or possible allergic reactions there.
  • A vaginal care composition is described by way of example hereinbelow, which composition comprises constituents in the following amounts (in the following, wt. % are always based on the total composition):
      • Lactobacillus/Bifidobacterium: from 107 to 1010 microorganisms/g, from 3 to 5% composition
      • Saccharomyces: from 0.1 to 40 wt. %
      • saccharide(s): from 1 to 40 wt. %
      • vitamin A: from 0.01 to 0.5 wt. %
      • zinc: from 0.2 to 10 wt. %.
  • The saccharide for the vaginal care composition is preferably selected from: oligofructose, inulin and/or lactose, preference being given to oligofructose. It is also possible to use a mixture of two or more of the above-mentioned saccharides. The saccharides serve especially as starting materials for the development of the Lactobacilli and Bifidobacteria. These utilize the saccharides and as a result have a growth advantage over other microorganisms.
  • The vaginal care composition may be so composed that the zinc is used in the form of zinc sulfate and/or zinc gluconate. The vaginal care composition may also have a formulation in which the vitamin A is used in the form of retinyl acetate and/or retinyl gluconate. These forms of addition of zinc and vitamin A are known to the person skilled in the art. Other forms of zinc and vitamin A can be chosen, provided that the function of the composition as a care composition for the vaginal mucosa is not impaired thereby.
  • Depending on its type, the composition may also comprise further conventional constituents, provided that they do not impair the function of a care composition. Such constituents may be selected, for example, from binders, excipients, solvents, stabilizers, lubricants, disintegrators and carriers, such as, for example, solid or liquid carriers.
  • According to a main aspect of the present invention, the vaginal care composition as defined above is used for the care of the vaginal mucosa and/or for preventing infections thereof by bacteria, fungi and/or viruses. The particular composition allows the vaginal mucosa to be cared for without being adversely affected or impaired. This care can take place on a regular basis or as required, for example in phases of hormonal change, such as, for example, during pregnancy, during lactation, in the menopause or post-menopausal. It is also possible to care for the mucosa in a very targeted manner, for example before and/or after visiting public bodies of water, such as, for example, bathing pools or swimming baths.
  • The vaginal care composition is preferably applied directly to the vaginal mucosa. This can be effected, for example, by introducing the composition into the vagina in the form of an ovule or a cream or ointment and thereby bringing it into direct contact with the mucosa. It is also possible for the composition to be contained in a tampon which is then inserted into the vagina, the composition thereby coming into contact with the mucosa. Finally, according to a further preferred embodiment, the composition is contained in a panty liner. The composition is in each case activated by moisture, for example the moisture of the usual vaginal environment. “Activation” in this context means that the Lactobacilli and/or Bifidobacteria contained therein begin to grow and multiply.
  • According to a particularly preferred embodiment, therefore, the present invention relates to a caring ovule comprising the vaginal care composition as defined above. The caring ovule having a weight of from 2 to 5 g, preferably 3 g, per ovule, preferably comprises the following per gram:
      • from 107 to 109, preferably 108, microorganisms/g, 5% Lactobacillus bifidus
      • from 1 to 10 wt. %, preferably 2.5 wt. %, Saccharomyces cerevisiae,
      • from 0.05 to 0.3 wt. %, preferably 0.1 wt. %, vitamin A,
      • from 1 to 3 wt. %, preferably 1.8 wt. %, -alpha-tocopherol,
      • from 0.4 to 1.5 wt. %, preferably 0.9 wt. %, pantothenate,
      • from 0.5 to 5 wt. %, preferably 0.8 wt. %, zinc,
      • from 0.002 to 0.02 wt. %, preferably 0.005 wt. %, selenium,
      • from 1 to 5 wt. %, preferably 3 wt. %, Melaleuca aetheroleum,
      • from 1 to 5 wt. %, preferably 3 wt. %, lavender oil,
      • from 0.2 to 3 wt. %, preferably 1 wt. %, camomile flower oil extract and/or
      • from 2 to 20 wt. %, preferably 5 wt. %, oligofructose.
    DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
  • The preferred composition of an ovule is summarized hereinbelow in table form, the combinatory action being indicated in each case:
    TABLE 1
    Formulation for 3 g vaginal ovules with Adeps solidus
    Microorganisms/g/ Formulation Content of pure
    Substance wt. % wt. % substance Action in the combination
    Lactobacillus bif. microorganisms/g 108/g 10 300 mg Repopulation or control of
    the vaginal flora
    Saccharomyces cer. wt. % 2.5 75 mg Nutrient medium for symbionts
    and vitamin B pool
    Retinol acetate wt. % 0.1 Vit. A 3 mg Care of mucosa and healing of wounds
    α-Tocopherol acet. wt. % 1.8 Vit. E 54 mg Antioxidant, care of mucosa and
    healing of wounds in microtraumas
    (Ca) pantothenate wt. % 0.9 B5 27 mg Care of mucosa and healing of wounds
    in microtraumas
    Zinc (sulfate) wt. % 0.8 Zn 24 mg Skin protection against Candida
    Selenium as yeast wt. % 0.005 Se 150 μg Antioxidant with cell-protecting
    functions
    Melaleuca aetherol. wt. % 3 90 mg Care oil for mucosa
    Camomile flower wt. % 1 30 mg Care of mucosa
    oil extract
    Lavender oil wt. % 3 90 mg Fragrance and care oil
    Oligofructose wt. % 5 150 mg Starter for Lactobacilli and
    saccharide-degrading
    symbionts present
  • Within the scope of the present invention, the term “ovule” is to include the solid forms, such as, for example, vaginal suppositories, for insertion into the vagina that are known by this name to the person skilled in the art, as well as foaming tablets or depot implants. An ovule preferably comprises the conventional bases, such as, for example, Whitepsol, Massa Estarinum, coconut fat, glycerol-gelatin compositions, glycerol soaps or polyethylene glycol. According to a further preferred embodiment, the present invention relates to a care cream comprising the vaginal composition as defined above. The care cream preferably comprises
      • from 107 to 109, preferably 108, microorganisms/g Lactobacillus bifidus, 5%,
      • from 1 to 10 wt. %, preferably 2.5 wt. %, Saccharomyces cerevisiae,
      • from 0.05 to 0.3 wt. %, preferably 0.1 wt. %, vitamin A,
      • from 1 to 3 wt. %, preferably 1.5 wt. %, D-alpha-tocopherol,
      • from 0.4 to 1.5 wt. %, preferably 0.7 wt. %, pantothenate,
      • from 1 to 6 wt. %, preferably 3 wt. %, zinc,
      • from 1 to 5 wt. %, preferably 2 wt. %, Melaleuca aetheroleum,
      • from 0.05 to 3 wt. %, preferably 1 wt. %, camomile flower extract,
      • from 2 to 20 wt. %, preferably 5 wt. %, oligofructose
      • and/or from 1 to 5 wt. %, preferably 3 wt. %, lavender oil.
  • According to a further preferred form, the care cream comprises further conventional cream or ointment constituents, especially constituents selected from the following group: sunflower oil, Tegomuls 90 S, cetyl alcohol, Cetaceum artificiale, Polysorbat 80, methyl 4-hydroxybenzoate, propyl 4-hydroxybenzoate, sesame oil, wool wax, yellow wax, wool wax alcohols, glycerol, glycerol esters, palmitic acid ester, white Vaseline, liquid wax, olive oil and/or distilled water.
  • The term “cream” within the scope of the present invention includes creams, ointments, as well as emulsions, and liquid compositions to be released from gelatin.
  • A particularly preferred ointment base is the following:
  • sunflower oil, Tegomuls 90 S, cetyl alcohol, Cetaceum artificiale, Polysorbat 80, methyl 4-hydroxybenzoate and propyl 5-hydroxybenzoate in distilled water, or sesame oil, wool wax, yellow wax, wool wax alcohols, or glycerol, glycerol ester, palmitic acid ester, white Vaseline, liquid wax, or yellow wax, olive oil.
  • According to a another embodiment, the invention relates to a caring vaginal tampon comprising the vaginal care composition as defined above. Particularly preferably, the caring vaginal tampon may comprise the following (comprising from 2 to 5 g, preferably 3 g, of the vaginal care composition per tampon) (per gram of composition):
      • from 107 to 109, preferably 108, microorganisms/g Lactobacillus bifidus, 5%,
      • from 1 to 10 wt. %, preferably 2.5 wt. %, Saccharomyces cerevisiae,
      • from 0.05 to 0.3 wt. %, preferably 0.1 wt. %, retinol acetate,
      • from 1 to 3 wt. %, preferably 1.5 wt. %, D-alpha-tocopherol,
      • from 1 to 6 wt. %, preferably 0.8 wt. %, zinc,
      • from 1 to 5 wt. %, preferably 2 wt. %, Melaleuca aetheroleum and/or
      • from 2 to 20 wt. %, preferably 3 wt. %, oligofructose.
  • In order that the composition can reach the vaginal mucosa as easily and quickly as possible, the caring vaginal tampon should contain the vaginal care composition on a superficial layer of the tampon, the composition being applied by spraying or immersion processes, for example. Optionally, the composition may also penetrate the entire tampon. According to a particularly preferred embodiment, the vaginal care composition can also be contained solely in a layer directly beneath the outer cover layer of the tampon.
  • The vaginal care composition of the present invention can be applied to any tampon known to the person skilled in the art or such a tampon can be impregnated with the composition. For example, the tampon consists of a form twisted in on itself, with grooves or indentations directed outwardly, i.e. towards the body of the wearer, which facilitate the passage of liquid into the inside of the tampon. The tampon preferably further has an outer, liquid-repelling layer and an inner liquid-storing layer. It advantageously also contains materials that swell in liquid, so that the tampon is able to adapt to the body shape of the particular wearer. For example, the tampon may have a cover layer comprising cellulose which swells on contact with liquid and without delay forms a gel, which facilitates insertion. Such a tampon is known to the person skilled in the art.
  • According to another embodiment, the vaginal care composition according to the present invention is contained in an outer layer of the tampon, without the invention being limited thereto.
  • According to a further embodiment, the invention relates to a caring panty liner comprising the vaginal care composition as defined above. Preferably, the caring panty liner, which comprises from 2 to 4 g, preferably 3 g, of the vaginal care composition per panty liner, comprises in 1 g of the composition:
      • from 107 to 109, preferably 108, microorganisms/g Lactobacillus bifidus, 5%,
      • from 1 to 10 wt. %, preferably 2.5 wt. %, Saccharomyces cerevisiae,
      • from 0.05 to 0.3 wt. %, preferably 0.1 wt. %, retinol acetate,
      • from 1 to 3 wt. %, preferably 1.5 wt. %, D-alpha-tocopherol,
      • from 1 to 6 wt. %, preferably 3 wt. %, zinc and/or
      • from 2 to 20 wt. %, preferably 3 wt. %, oligofructose.
  • The caring panty liner can contain the vaginal care composition on an upper layer, preferably applied by a spraying process. It is also possible to form the caring panty liner in such a manner that the vaginal care composition is contained solely in a layer directly beneath the cover layer of the panty liner.
  • The vaginal care composition can be applied to/introduced onto any panty liner known to the person skilled in the art. For example, the panty liner may consist of a moisture-permeable cover layer, a moisture-repelling layer arranged beneath it, a moisture-storing layer arranged beneath the moisture-repelling layer, and a backing layer that is impermeable to liquid. The cover layer may have pores, for example, which facilitate the drawing off of liquid and improve aeration. Masking substances which improve the appearance of the panty liner may also be present. The vaginal care composition of the present invention is particularly preferably contained in a layer beneath the cover layer, without the invention being limited thereto.
  • In a further embodiment, the present care composition of the invention can also be used as a urethra stick for caring for the urethral mucosa in the case of partner care for men. The care composition in this embodiment may be embedded, for example, in a urethra stick of Adeps solidus. This stick should have a length of from 10 to 30 cm, preferably 25 cm, and a diameter of from 2.5 to 7 mm, preferably 4.5 mm. It can be broken into segments by means of predetermined breaking points, which are arranged, for example, at intervals of about 5 cm.
  • A preferred composition for the urethra stick consists of Lactobacillus bifidus microorganisms, with Saccharomyces cerevisiae and oligofructose as starter. Vitamin A, alpha-tocopherol, pantothenate, zinc, selenium, Melaleuca aetheroleum and fragrances should also be present. Preferably, the urethra stick comprises, per gram:
      • from 107 to 109, preferably 108 , Lactobacillus bifidus microorganisms,
      • from 1 to 10 wt. %, preferably 2.5 wt. %, Saccharomyces cerevisiae,
      • from 0.05 to 0.3 wt. %, preferably 0.1 wt. %, retinol acetate,
      • from 1 to 3 wt. %, preferably 1.5 wt. %, D-alpha-tocopherol,
      • from 1 to 6 wt. %, preferably 3 wt. %, zinc and/or
      • from 2 to 20 wt. %, preferably 3 wt. %, oligofructose.
  • The dosage of the vaginal care composition according to the invention is dependent on factors known to the person skilled in the art; care of the mucosa is usually to be carried out from 1 to 3 times daily using up to 3 g of the composition; alternatively, immediately before and after particular stress, such as swimming or sexual intercourse. Long-term care can be carried out using, for example, 6 ovules per cycle.
    • EXAMPLES
  • 1. Ointment
  • A. Preparation, Composition
  • An ointment having the following composition was prepared:
      • 108 microorganisms/g Lactobacillus bifidus (/g) 10% of the composition according to the invention
      • 2.5 wt. % Saccharomyces cerevisiae, as nutrient medium
      • 0.1 wt. % retinyl acetate
      • 0.8 wt. % D-alpha-tocopherol
      • 0.9 wt. % pantothenate
      • 0.8 wt. % zinc
      • 0.005 wt. % selenium (as selenium-containing yeast)
      • 3 wt. % Melaleuca aetheroleum
      • 1 wt. % camomile flower extract
      • 3 wt. % lavender oil
      • 5 wt. % oligofructose mixed according to the processes known to the person skilled in the art for the preparation of ointments in a mixture of yellow wax and olive oil.
        B. Application
  • A woman (25 years old, taking the pill) who in the past 5 years had suffered several vaginal mycoses, in each case in the summer, used the above ointment according to the following directions:
  • Once daily, in the evening, 3 g of the ointment were distributed over the vaginal mucosa. Care was begun in May. During the following summer months, no mycoses occurred.
  • 2. Ovule
  • A. Preparation, Composition
  • Each ovule weighed 3 g and was prepared from the following mixture according to the processes known to the person skilled in the art for the preparation of ovules:
      • 108 Lactobacillus bifidus microorganisms/g, 5% of the composition according to the invention
      • 2.5 wt. % Saccharomyces cerevisiae, as a culture
      • 0.1 wt. % retinyl acetate
      • 1.5 wt. % D-alpha-tocopherol
      • 0.7 wt. % pantothenate
      • 0.8 wt. % zinc
      • 0.005 wt. % selenium (as selenium-containing yeast)
      • 2 wt. % Melaleuca aetheroleum
      • 1 wt. % camomile flower extract
      • 3 wt. % lavender oil
      • 3 wt. % oligofructose
        The ingredients were mixed into Adeps solidus having a melting point of 34.5 degrees Celsius.
        B. Application
  • A woman (43 years old) who in previous years had suffered about 3 to 5 vaginal mycoses per year used the ovules, starting in January, according to the following directions: An ovule is inserted once daily, in the evening. Thereafter she was free of vaginal infections for the remainder of the year.
  • The above Examples and the description are intended to illustrate the invention further without limiting the scope thereof, which is defined by the claims.

Claims (35)

1. Vaginal care composition, comprising viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s); vitamin A/retinol, and zinc.
2. The vaginal care composition according to claim 1, wherein the Lactobacillus microorganism comprises Lactobacillus bifidus.
3. The vaginal care composition according to claim 1, wherein the non-viable Saccharomyces culture comprises Saccharomyces cerevisiae
4. Vaginal care composition according to claim 1, further comprising comprises selenium,
5. Vaginal care composition according to claim 1, wherein the selenium comprises selenium-containing yeast, in an amount of from 0.001 to 0.06 wt. % selenium.
6. Vaginal care composition according to claim 1, further comprising Melaleuca aetheroleum or camomile flower extract.
7. Vaginal care composition according to claim 1, additionally comprising D-alpha-tocopherol or pantothenate.
8. Vaginal care composition according to claim 1, additionally comprising fragrances.
9. Vaginal care composition according to claim 8, wherein the fragrance comprises lavender oil in an amount of from 0.5 to 10 wt. %.
10. Vaginal care composition according to claim 1, further comprising cocoa butter or a hard-fat carrier as base.
11. Vaginal care composition according to claim 1, wherein the composition comprises the constituents in the following amounts:
Lactobacillus/Bifidobacterium: from 107 to 1010 microorganisms/g of composition, 5%
Saccharomyces: from 0.1 to 40 wt. %
saccharide(s): from 1 to 40 wt. %
vitamin A: from 0.01 to 0.5 wt. %
zinc: from 0.2 to 10 wt. %.
12. Vaginal care composition according to claim 1, wherein the saccharide is selected from: oligofructose, inulin or lactose.
13. Vaginal care composition according to claim 1, wherein the zinc is in the form of zinc sulfate or zinc gluconate.
14. Vaginal care composition according to claim 1, wherein the vitamin A is in the form of retinyl acetate or retinyl gluconate.
15. Method of caring for the vaginal mucosa and for preventing infections thereof by bacteria, fungi and/or viruses, comprising administering an effective amount of a composition comprising viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s); vitamin A/retinol, and zinc.
16. The method according to claim 11, wherein the composition is applied directly to the vaginal mucosa.
17. An ovule, comprising a composition comprising viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s); vitamin A/retinol, and zinc.
18. Ovule according to claim 17, having a weight of 3 g per ovule, comprising per gram:
from 107 to 109 , Lactobacillus bifidus microorganisms/g, 5%,
from 1 to 10 wt. % Saccharomyces cerevisiae,
from 0.05 to 0.3 wt. % vitamin A,
from 1 to 3 wt. % D-alpha-tocopherol,
from 0.4 to 1.5 wt. % pantothenate,
from 0.5 to 5 wt. % zinc,
from 0.002 to 0.02 wt. % selenium,
from 1 to 5 wt. % Melaleuca aetheroleum,
from 1 to 5 wt. % lavender oil,
from 0.2 to 3 wt. % camomile flower oil extract and/or
from 2 to 20 wt. % oligofructose.
19. Ovule according to claim 17, wherein the ovule is composed of coconut oil, glycerol-gelatin or polyethylene glycol.
20. Ovule according to claim 17, wherein the ovule further comprises cocoa butter or hard fats.
21. Care cream comprising composition comprising viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s); vitamin A/retinol, and zinc
22. Care cream according to claim 21, comprising
from 107 to 109 Lactobacillus bifidus microorganisms/g, 5%,
from 1 to 10 wt. %, Saccharomyces cerevisiae,
from 0.05 to 0.3 wt. % vitamin A,
from 1 to 3 wt. % D-alpha-tocopherol,
from 0.4 to 1.5 wt. % pantothenate,
from 1 to 6 wt. % zinc,
from 1 to 5 wt. % Melaleuca aetheroleum,
from 0.05 to 3 wt. % camomile flower extract,
from 2 to 20 wt. % oligofructose or from 1 to 5 wt. %, lavender oil.
23. Care cream according to claim 22, wherein the cream further comprises constituents selected from the following group: sunflower oil, Tegomuls 90 S, cetyl alcohol, Cetaceum artificiale, Polysorbat 80, methyl 4-hydroxybenzoate, propyl 4-hydroxybenzoate, sesame oil, wool wax, yellow wax, wool wax alcohols, glycerol, glycerol esters, palmitic acid ester, white Vaseline, liquid wax, olive oil and distilled water.
24. Vaginal tampon comprising the vaginal care composition comprising viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s); vitamin A/retinol, and zinc.
25. Vaginal tampon according to claim 20, comprising from 2 to 4 g, of the vaginal care composition per tampon, comprising per gram of the composition:
from 107 to 109 Lactobacillus bifidus microorganisms/g, 5%,
from 1 to 10 wt. %, Saccharomyces cerevisiae,
from 0.05 to 0.3 wt. % retinol acetate,
from 1 to 3 wt. %, D-alpha-tocopherol,
from 1 to 6 wt. % zinc,
from 1 to 5 wt. % Melaleuca aetheroleum or
from 2 to 20 wt. % oligofructose.
26. Vaginal tampon according to claim 24, comprising a liquid-repellent outer layer and an inner, storage layer.
27. Vaginal tampon according to claim 24, wherein the vaginal care composition is applied to a superficial layer of the tampon by spraying or immersing processes or the composition penetrates the entire tampon.
28. Vaginal tampon according to claim 24, wherein the vaginal care composition is contained solely in a layer directly beneath an outer cover layer of the tampon.
29. Vaginal tampon according to claim 24, wherein the vaginal care composition is activated by moisture.
30. A panty liner, comprising a vaginal care composition comprising viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s); vitamin A/retinol, and zinc.
31. Panty liner according to claim 30, comprising from 2 to 5 g of the vaginal care composition per panty liner, 1 g of the composition comprising:
from 107 to 109 Lactobacillus bifidus microorganisms/g, 5%,
from 1 to 10 wt. % Saccharomyces cerevisiae,
from 0.05 to 0.3 wt. % retinol acetate,
from 1 to 3 wt. % D-alpha-tocopherol,
from 1 to 6 wt. % zinc and/or
from 2 to 20 wt. % oligofructose.
32. Panty liner according to claim 30, further comprising a cover layer, a liquid-repelling layer, a storage layer and a backing layer.
33. Panty liner according to claim 30, wherein the vaginal care composition is applied to an upper layer by a spraying process or one or more further layers are provided therewith.
34. Panty liner according to claim 30, wherein the vaginal care composition is contained solely in a layer directly beneath the cover layer of the panty liner.
35. Panty liner according to claim 1, wherein the vaginal care composition is activated by moisture.
US10/977,742 2003-11-03 2004-10-29 Vaginal care composition Abandoned US20050095232A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/599,965 US7670606B2 (en) 2003-11-03 2006-11-15 Method for administering a vaginal care composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025152.4 2003-11-03
EP03025152A EP1506781B1 (en) 2003-11-03 2003-11-03 Vaginal care composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/599,965 Division US7670606B2 (en) 2003-11-03 2006-11-15 Method for administering a vaginal care composition

Publications (1)

Publication Number Publication Date
US20050095232A1 true US20050095232A1 (en) 2005-05-05

Family

ID=33560815

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/977,742 Abandoned US20050095232A1 (en) 2003-11-03 2004-10-29 Vaginal care composition
US11/599,965 Expired - Fee Related US7670606B2 (en) 2003-11-03 2006-11-15 Method for administering a vaginal care composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/599,965 Expired - Fee Related US7670606B2 (en) 2003-11-03 2006-11-15 Method for administering a vaginal care composition

Country Status (24)

Country Link
US (2) US20050095232A1 (en)
EP (1) EP1506781B1 (en)
JP (1) JP4863612B2 (en)
KR (1) KR101092731B1 (en)
CN (1) CN1636577B (en)
AR (1) AR046218A1 (en)
AT (1) ATE289514T1 (en)
AU (1) AU2004226910B2 (en)
BR (1) BRPI0404688B8 (en)
CA (1) CA2486473C (en)
DE (1) DE50300325D1 (en)
DK (1) DK1506781T3 (en)
ES (1) ES2237732T3 (en)
HK (1) HK1079109A1 (en)
IL (1) IL164637A0 (en)
MX (1) MXPA04010893A (en)
NO (1) NO332400B1 (en)
NZ (1) NZ536261A (en)
PL (1) PL213027B1 (en)
PT (1) PT1506781E (en)
RU (1) RU2369389C2 (en)
SG (1) SG111283A1 (en)
SI (1) SI1506781T1 (en)
ZA (1) ZA200408882B (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274162A1 (en) * 2007-05-04 2008-11-06 Jeffrey Nessa Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository
WO2012154243A1 (en) * 2011-02-21 2012-11-15 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoic acid oligomer esters of retinol
AU2008351414B2 (en) * 2008-02-27 2013-09-12 Clji I.P. Company, Llc Topical formulations for the prevention of sexually transmitted disease and methods of producing the same
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
US20140065116A1 (en) * 2011-03-17 2014-03-06 Giovanni Mogna Probiotic bacteria having antioxidant activity and use thereof
US20140220155A1 (en) * 2011-07-21 2014-08-07 University Of Miami Vaginal tissue rejuvenation compositions and methods
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US9492377B2 (en) 2011-01-28 2016-11-15 Probiotical S.P.A. Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
US9925224B2 (en) 2011-05-09 2018-03-27 Probiotical S.P.A. Bacterial strains belonging to the genus bifidobacterium for use in the treatment of hypercholesterolaemia
US10028982B2 (en) 2011-09-09 2018-07-24 Probiotical North America Inc. Composition comprising N-acetylcysteine and/or microencapsulated gastroprotected lysozyme in association with probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during the pharmacological treatment of gastric hyperacidity
US10286017B2 (en) 2011-05-09 2019-05-14 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food
US10384847B2 (en) 2011-09-23 2019-08-20 Probiotical North America Inc. Material impermeable to humidity and oxygen for packaging dietary products, cosmetics and medicinal specialities
GR1009621B (en) * 2018-07-25 2019-10-23 Ιουλια Κλεωνος Τσετη Locally applied compositions containing boric acid, tea tree oil, panthenol and bisabolol for the treatment of mycosis-associated infections
CN110840918A (en) * 2019-11-25 2020-02-28 无锡宾西利悦科技有限公司 Vaginal microecological composition for women
EP3626230A1 (en) 2014-05-15 2020-03-25 Grünenthal GmbH Device and formulation for topical treatment of pain affecting the vulvar area of the female human genital organ
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
DE102006017672B4 (en) * 2006-04-12 2008-07-03 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Composition for use as a laxative
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
CN101500583B (en) * 2006-07-12 2012-05-23 控制治疗（苏格兰）有限公司 Drug delivery polymer with hydrochloride salt of clindamycin
CA2662116C (en) * 2006-08-29 2013-03-26 Playtex Products, Inc. Tampon removal device
US8409557B2 (en) 2006-09-28 2013-04-02 Clji Ip Company, Llc Topical formulations for the prevention of sexually transmitted disease and methods of producing the same
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US20090156987A1 (en) * 2007-12-14 2009-06-18 Mclean Barbara Wanamaker Apparatus and method of delivery of substances into target tissue
EP2243482A1 (en) * 2009-04-20 2010-10-27 Polichem SA Use of nifuratel to treat infections caused by atopobium species
GB0915315D0 (en) * 2009-09-03 2009-10-07 Univ Manchester Use of non-digestible oligosaccharides
DK2338476T3 (en) * 2009-12-02 2012-09-17 Bettina Heil Suppository for rectal, vaginal or urethral administration containing a probiotic, an antibiotic and an unsaturated non-esterified fatty acid
EP2420228A1 (en) * 2010-08-05 2012-02-22 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
FR2981273B1 (en) * 2011-10-14 2013-12-20 Gilles Andre Yves Bhat NEW COMPOSITION FOR MUCOUS MEMBRANES: TOCOPHEROL, OILY MACERATE OF CALENDULA FLOWERS IN MUSKLE ROSE OIL, RETINOL PALMITATE, UBIQUINONE, ASCORBYL PALMITATE AND LACTOBACILLUS
US20130108599A1 (en) * 2011-10-31 2013-05-02 Tamyra Comeaux Herbal Vaginal Compositions
FR2993179B1 (en) * 2012-07-13 2016-01-08 Lesaffre & Cie YEAST SACCHAROMYCES CEREVISIAE FOR PREVENTING AND / OR TREATING VAGINAL MYCOSES
RU2504580C1 (en) * 2012-08-01 2014-01-20 Вячеслав Михайлович Абрамов PROBIOTIC STRAINS Lactobacillus AND THEIR CONSORTIUM FOR PROPHYLAXIS AND TREATMENT OF UROGENITAL INFECTIOUS DISEASES OF FEMALES
CN103114439B (en) * 2013-01-24 2015-01-07 量子高科(中国)生物股份有限公司 Non-woven fabric with biological regulation function and preparation method thereof
CN103735601B (en) * 2013-12-31 2016-10-05 哈尔滨欧替药业有限公司 Herba Orostachyos vaginal expansion plug and preparation method thereof and detection method
MY192494A (en) 2014-03-13 2022-08-24 Singapore Ze&Z Int Pte Ltd Vaginal composition and use thereof
DE102014119576A1 (en) * 2014-12-23 2016-06-23 Ernst-Moritz-Arndt-Universität Greifswald Pharmaceutical form for administration to mucous membranes
CN105434605A (en) * 2015-06-03 2016-03-30 马南行 Composition for vaginal nursing balancing therapy and preparation method thereof
US10857094B2 (en) * 2015-09-02 2020-12-08 Eric A. Weiss Lubricating and moisturizing composition for human use
CN105232231A (en) * 2015-11-10 2016-01-13 湖北民族学院 Selenium-rich hygienic product and preparation method thereof
CN105748492A (en) * 2016-02-16 2016-07-13 王冬颖 Sugar ligand preparation capable of inhibiting growth of candida albicans
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2017177063A1 (en) 2016-04-06 2017-10-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of heterodimeric il-15 in adoptive cell transfer
KR101784847B1 (en) * 2016-05-10 2017-10-13 주식회사 하우동천 A composition comprising lactic acid bacteria for protecting and treating vaginosis disease and the use thereof
TW201825511A (en) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 Oncolytic virus expressing immune checkpoint modulators
IT201700037319A1 (en) 2017-04-05 2018-10-05 Moss S P A NATURAL COMPOSITION FOR USE IN GYNECOLOGY
DE202017105515U1 (en) * 2017-08-07 2018-08-09 Boris Vestweber Composition, in particular for the care of the intimate or vaginal area
CN110353885A (en) * 2018-04-11 2019-10-22 常州英莱克斯生物工程有限公司 A kind of tapon good without applicator moisture absorption
CN114015674A (en) 2021-11-02 2022-02-08 辉二(上海)生物科技有限公司 Novel CRISPR-Cas12i system

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702714A (en) * 1995-06-07 1997-12-30 Goss; Louis Skin conditioner
US20020015990A1 (en) * 1996-12-12 2002-02-07 Mamoru Tomita Lactobacillus bifidus growth promoting composition and use thereof
US20030003107A1 (en) * 1997-04-18 2003-01-02 Sean Farmer Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof
US20030003138A1 (en) * 2000-01-18 2003-01-02 Achille Di Cintio Articles with spores exhibiting antagonistic properties against pathogens and/or spores forming micro-organisms
US6783780B1 (en) * 1998-12-09 2004-08-31 N.V. Nutricia Preparation that contains oligosaccharides and probiotics
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
US20050226949A1 (en) * 2001-02-02 2005-10-13 Bland Jeffrey S Medical composition for managing hormone balance
US20060018986A1 (en) * 2002-12-13 2006-01-26 L'oreal Extracts of decaffeinated coffee beans and orally administrable compositions comprised thereof for stimulating the sebaceous function of the skin
US20060057132A1 (en) * 2002-10-15 2006-03-16 Vsl Pharmaceuticals, Inc. Identifying and treating vaginal infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS588018A (en) * 1981-07-07 1983-01-18 Akira Yamauchi Cathartic
NO178843C (en) * 1988-07-11 1996-06-19 Sspl Sa Safe Sex Prod Licens Process for the preparation of a pharmaceutical composition for the prevention of sexually transmitted diseases
SE9100364L (en) * 1991-02-05 1992-08-06 Bac Dev In Sweden Ab TAMPON OR BIND IMPREGNATED WITH A CULTURE OF LIVING Lactic Acid Bacteria INTENDED TO REDUCE THE RISK OF UNROGENITAL INFECTIONS
JPH0710740A (en) * 1993-04-26 1995-01-13 Meiji Milk Prod Co Ltd Melamine production-inhibiting agent
US6093394A (en) * 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
PT956858E (en) * 1998-04-30 2002-04-29 Renata Maria Anna Caval Vesely PHARMACEUTICAL COMPOSITIONS CONTAINING LACTOBACILS FOR THE TREATMENT OF VAGINAL INFECTIONS
JP2000217566A (en) * 1999-01-25 2000-08-08 Bhph Co Ltd Culture medium for lactobacillus clearans and storage of strain thereof
IT1306716B1 (en) * 1999-06-21 2001-10-02 Mendes S U R L ASSOCIATION OF LACTIC BACTERIA AND ITS USE FOR THE PREVENTION AND / OR THERAPEUTIC TREATMENT OF INFECTIONS AND INFLAMMATORY STATES.
CZ288454B6 (en) * 1999-08-10 2001-06-13 Miroslav Mvdr Mahel Healing preparations for early postnatal problems and mastitis of domestic animals
EP1118340A1 (en) 2000-01-18 2001-07-25 The Procter & Gamble Company Articles having an odour control system comprising lactic-acid producing micro-organisms and an odour absorbing agent
BR0002018A (en) 2000-05-26 2002-01-02 Eltecom Empreendimentos E Part Use of pharmaceutical compositions from saccharomyces cerevisiae for the treatment of vaginal infections
SE521022C2 (en) * 2001-09-20 2003-09-23 Ellen Ab Lactic acid producing bacteria for use as probiotic organisms in the human vagina
JP3484428B2 (en) * 2001-05-31 2004-01-06 明王物産株式会社 Method for producing yeast extract
EP1480517A4 (en) * 2002-02-07 2007-08-22 Univ Columbia Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
ITMI20020399A1 (en) * 2002-02-28 2003-08-28 Ct Sperimentale Del Latte S P DIETARY AND / OR PHARMACEUTICAL COMPOSITIONS FOR HUMAN AND / OR ANIMAL USE BASED ON MICROBIAL PROBIOTIC PREPARATIONS
WO2003080813A2 (en) 2002-03-21 2003-10-02 Bifodan A/S Lactobacillus strains
US7829079B2 (en) 2002-03-28 2010-11-09 Christian Hansen A/S Lactobacillus iners for the enhancement of urogenital health
JP4712289B2 (en) * 2003-08-26 2011-06-29 株式会社エイ・エル・エイ Immune promoting composition

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702714A (en) * 1995-06-07 1997-12-30 Goss; Louis Skin conditioner
US20020015990A1 (en) * 1996-12-12 2002-02-07 Mamoru Tomita Lactobacillus bifidus growth promoting composition and use thereof
US20030003107A1 (en) * 1997-04-18 2003-01-02 Sean Farmer Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof
US6783780B1 (en) * 1998-12-09 2004-08-31 N.V. Nutricia Preparation that contains oligosaccharides and probiotics
US20030003138A1 (en) * 2000-01-18 2003-01-02 Achille Di Cintio Articles with spores exhibiting antagonistic properties against pathogens and/or spores forming micro-organisms
US20050226949A1 (en) * 2001-02-02 2005-10-13 Bland Jeffrey S Medical composition for managing hormone balance
US20060057132A1 (en) * 2002-10-15 2006-03-16 Vsl Pharmaceuticals, Inc. Identifying and treating vaginal infections
US20060018986A1 (en) * 2002-12-13 2006-01-26 L'oreal Extracts of decaffeinated coffee beans and orally administrable compositions comprised thereof for stimulating the sebaceous function of the skin
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274162A1 (en) * 2007-05-04 2008-11-06 Jeffrey Nessa Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository
AU2008351414B2 (en) * 2008-02-27 2013-09-12 Clji I.P. Company, Llc Topical formulations for the prevention of sexually transmitted disease and methods of producing the same
US9532938B2 (en) 2010-07-29 2017-01-03 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
US9492377B2 (en) 2011-01-28 2016-11-15 Probiotical S.P.A. Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
WO2012154243A1 (en) * 2011-02-21 2012-11-15 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoic acid oligomer esters of retinol
US8329938B2 (en) 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
US20140065116A1 (en) * 2011-03-17 2014-03-06 Giovanni Mogna Probiotic bacteria having antioxidant activity and use thereof
US9925224B2 (en) 2011-05-09 2018-03-27 Probiotical S.P.A. Bacterial strains belonging to the genus bifidobacterium for use in the treatment of hypercholesterolaemia
US10286017B2 (en) 2011-05-09 2019-05-14 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
US9375450B2 (en) * 2011-07-21 2016-06-28 Peter Takacs Vaginal tissue rejuvenation compositions and methods
US20140220155A1 (en) * 2011-07-21 2014-08-07 University Of Miami Vaginal tissue rejuvenation compositions and methods
US10028982B2 (en) 2011-09-09 2018-07-24 Probiotical North America Inc. Composition comprising N-acetylcysteine and/or microencapsulated gastroprotected lysozyme in association with probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during the pharmacological treatment of gastric hyperacidity
US10384847B2 (en) 2011-09-23 2019-08-20 Probiotical North America Inc. Material impermeable to humidity and oxygen for packaging dietary products, cosmetics and medicinal specialities
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
EP3626230A1 (en) 2014-05-15 2020-03-25 Grünenthal GmbH Device and formulation for topical treatment of pain affecting the vulvar area of the female human genital organ
US10765848B2 (en) 2014-05-15 2020-09-08 Gruenenthal Gmbh Device and formulation for topical treatment of pain affecting the vulvar area of the female human genital organ
GR1009621B (en) * 2018-07-25 2019-10-23 Ιουλια Κλεωνος Τσετη Locally applied compositions containing boric acid, tea tree oil, panthenol and bisabolol for the treatment of mycosis-associated infections
CN110840918A (en) * 2019-11-25 2020-02-28 无锡宾西利悦科技有限公司 Vaginal microecological composition for women

Also Published As

Publication number Publication date
SG111283A1 (en) 2005-05-30
KR101092731B1 (en) 2011-12-09
RU2369389C2 (en) 2009-10-10
ES2237732T3 (en) 2005-08-01
PL213027B1 (en) 2012-12-31
PT1506781E (en) 2005-07-29
DK1506781T3 (en) 2005-06-13
KR20050042455A (en) 2005-05-09
CA2486473A1 (en) 2005-05-03
BRPI0404688B1 (en) 2016-10-11
ZA200408882B (en) 2005-09-28
JP2005139176A (en) 2005-06-02
CA2486473C (en) 2014-01-21
JP4863612B2 (en) 2012-01-25
HK1079109A1 (en) 2006-03-31
RU2004132058A (en) 2006-04-10
BRPI0404688A (en) 2005-07-12
BRPI0404688B8 (en) 2021-05-25
ATE289514T1 (en) 2005-03-15
SI1506781T1 (en) 2005-08-31
US7670606B2 (en) 2010-03-02
CN1636577A (en) 2005-07-13
EP1506781A1 (en) 2005-02-16
AU2004226910B2 (en) 2009-12-10
CN1636577B (en) 2012-05-09
MXPA04010893A (en) 2005-10-26
PL370970A1 (en) 2005-05-16
EP1506781B1 (en) 2005-02-23
US20070059298A1 (en) 2007-03-15
AU2004226910A1 (en) 2005-05-19
DE50300325D1 (en) 2005-03-31
AR046218A1 (en) 2005-11-30
NZ536261A (en) 2005-03-24
NO20044699L (en) 2005-05-04
NO332400B1 (en) 2012-09-10
IL164637A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
US7670606B2 (en) Method for administering a vaginal care composition
US11590068B2 (en) Personal care products
CN101646415A (en) At least a monounsaturated fatty acid is used to improve the oral use of hair
CN103330658A (en) Skin care composition with functions of repairing damaged skin surface lipid film and relieving skin pressure
EP2238981B1 (en) Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
US20080107743A1 (en) Composition and method for enhancing skin cell growth, proliferation and repair
CA3189156A1 (en) Silybum marianum (l.) gaertn. oil for reinforcing the barrier function of the skin
JPH07278001A (en) External preparation for skin and bathing agent
KR102228690B1 (en) Hypoallergenic vulvar cleaner composition that helps with excellent antibacterial effect and itchiness relief
CN116869855B (en) Skin care composition containing collagen
KR101866518B1 (en) A cosmetic composition for manufacturing by the using of propolis improving onychomycosis
KR102036988B1 (en) Preparing method for capsulated female cleansing composition and capsulated female cleasing composition thereof
WO2022255978A1 (en) A composition against genital odors
Hedrach Researches on the development of technology of combined antifungal suppositories for use in gynecology
RU2104028C1 (en) Hepatoprotective, holagogue, antiulcer, antiseptic, antisclerotic and antiproliferative with respect to prostate cells agent
CN116669701A (en) Extracts of Sphingomonas bacteria
KR20230033519A (en) Feminine cleansing composition containing human stem cell culture
KR20210010682A (en) Cleansing composition for women's vagina comprising natural
FR3115459A1 (en) Paeonia x suffruticosa Andrews oil for skin and hair protection

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION